AbbVie (ABBV) Q2 2024: Ex-Humira Platform Delivers $6B Growth as Immunology, Neuroscience Outperform
AbbVie’s diversified growth engine outpaced expectations, propelled by immunology and neuroscience, while aesthetics moderated on macro softness. Management raised full-year guidance again, signaling continued confidence in the ex-Humira portfolio’s momentum, even as Humira erosion and Medicare changes loom. Investor focus now shifts to the sustainability of high-single-digit growth as pipeline innovation and business development drive AbbVie’s next decade.
Summary
- Immunology Outperformance: Skyrizi and Rinvoq continued to drive robust share gains across multiple indications.
- Pipeline and BD Depth: Early-stage deals and late-stage assets position AbbVie for post-2025 growth.
- Aesthetics Headwinds: Macroeconomic drag in the U.S. and China tempers near-term outlook, but long-term targets reaffirmed.
Business Overview
AbbVie is a global biopharmaceutical company generating revenue through branded prescription drugs, with major segments including immunology (autoimmune and inflammatory diseases), oncology (cancer therapies), neuroscience (CNS and migraine), and aesthetics (Botox and fillers). Its business model relies on a mix of established blockbusters and a rapidly expanding pipeline, balancing legacy assets like Humira with new launches and acquisitions to sustain growth.
Performance Analysis
AbbVie delivered operational revenue growth of 5.6% in Q2, outperforming expectations and driving a second consecutive guidance raise for 2024. The ex-Humira growth platform, now accounting for over 80% of total sales, added more than $6 billion in annualized growth, led by immunology (Skyrizi and Rinvoq) and neuroscience (notably Vraylar, Ubrelvy, and Qulipta). Oncology remained mixed as Imbruvica declined on competition, but Venclexta and Elahere showed strong momentum, and new solid tumor assets advanced.
Aesthetics sales grew modestly, constrained by weaker procedure volumes and economic headwinds in key markets, with U.S. injectables offset by declines in China. Humira’s global sales continued their expected slide, down nearly 29% operationally, as biosimilar competition and formulary changes played out. Despite these legacy headwinds, AbbVie’s margin discipline and pipeline progress preserved operating leverage, with adjusted operating margin at 42.6% even after absorbing R&D and business development costs.
- Immunology Leadership: Skyrizi and Rinvoq combined for over $4.1 billion in quarterly sales, up 50% operationally, supported by broad indications and clear clinical differentiation.
- Neuroscience Acceleration: The segment grew 15.2% operationally, with Vraylar and migraine assets gaining share and pipeline catalysts (Cerevel, 951) on deck.
- Aesthetics Underperformance: U.S. and China demand lagged expectations, prompting a $200 million guidance reduction for Botox and Juvederm, though long-term targets remain unchanged.
AbbVie’s outperformance was broad-based, but the quarter also revealed the company’s reliance on its new launches and the importance of pipeline execution as Humira’s contribution continues to fade.
Executive Commentary
"Our ex-Humira growth platform, which covers more than 80% of AbbVie’s total sales, will outperform our initial full-year sales guidance by more than $1 billion, driven by strong performance in immunology and oncology."
Rob Michael, Chief Executive Officer
"We are raising guidance for the second time this year, underscoring our confidence in the business. The robust performance of our growth platform and the advancement of our pipeline supports AbbVie’s top-tier long-term outlook."
Rob Michael, Chief Executive Officer
Strategic Positioning
1. Immunology Platform: Share Capture and Indication Expansion
Skyrizi and Rinvoq, the backbone of AbbVie’s immunology franchise, are achieving both volume and share gains across psoriasis, Crohn’s, ulcerative colitis, and atopic dermatitis. Skyrizi now leads in U.S. Crohn’s “in-play” share, outpacing Stelara by 13 points, and recent UC approval adds another growth lever. The company’s sophisticated commercial approach, with tailored sales teams and robust payer contracts, enables simultaneous frontline and later-line positioning, minimizing cannibalization and maximizing market coverage.
2. Neuroscience: Pipeline Augmentation and Franchise Expansion
Neuroscience delivered double-digit growth, and the pending Cerevel acquisition will further diversify the pipeline with late-stage assets in schizophrenia and Parkinson’s. Vraylar’s preferred status in bipolar disorder and AMDD, combined with flexible dosing and favorable tolerability, underpins continued share gains even as competition increases. Management expects the segment to remain a key growth pillar through new indications and launches.
3. Oncology: Diversification Beyond Hematology
While Imbruvica faces ongoing erosion, AbbVie is pivoting toward solid tumors and next-generation therapies, with Elahere, Teliso-V, and ABBV-400 advancing in ovarian and lung cancer. The pipeline also includes bispecifics and ADCs, aiming to offset legacy declines and capture new patient populations. Venclexta’s momentum in CLL and AML, and Epkinley’s dual lymphoma indications, support near-term growth.
4. Aesthetics: Navigating Macro and Market Cycles
Aesthetics remains strategically important, but near-term growth is challenged by macro softness and lower-than-expected procedure volumes in the U.S. and China. Despite this, AbbVie maintains market leadership in facial injectables and is launching new indications (e.g., Botox for masseter muscle prominence in China, Juvederm Voluma XC for temple hollowing in the U.S.) to drive patient activation and defend share. Management reaffirmed the $9 billion 2029 target, betting on low penetration and innovation-led recovery.
5. Business Development and Pipeline Strategy
AbbVie executed nearly a dozen early-stage deals in 2024, targeting next-generation immunology, oncology, and neuroscience assets, including multispecifics and novel mechanism therapies. The focus is on building out the late-2020s and 2030s growth engine as the current portfolio matures. Management emphasized that near-term BD will prioritize early-stage opportunities over large-scale M&A, balancing long-term growth with margin discipline.
Key Considerations
This quarter underscores AbbVie’s transition from Humira dependence to a diversified, innovation-driven growth model. The company’s execution in immunology and neuroscience is offsetting legacy erosion and macro drag in aesthetics, but the sustainability of high-single-digit growth will depend on continued pipeline success and commercial agility.
Key Considerations:
- Immunology Share Gains Accelerate: Skyrizi and Rinvoq benefit from biosimilar disruption, with 20% of Humira switches favoring new mechanisms—an upside for AbbVie’s newer assets if trends persist.
- Pipeline Execution is Critical: Multiple late-stage readouts, regulatory submissions, and new launches (e.g., Skyrizi UC, 951, Cerevel assets) are needed to maintain momentum as Humira and Imbruvica decline.
- Aesthetics Recovery Hinges on Macro: Management expects long-term growth to rebound as economic conditions improve, but near-term performance is muted, especially in China and the U.S.
- Margin Discipline Offsets R&D Spend: Operating margin expansion is expected to be balanced by higher interest expense from recent acquisitions, keeping EPS growth in line with revenue.
- Medicare Part D, IRA, and Pricing Pressures: Management anticipates a 3% headwind from Medicare redesign in 2025, with additional risk from U.S. policy changes impacting pricing and innovation incentives.
Risks
AbbVie’s growth outlook is exposed to continued Humira and Imbruvica erosion, potential access and pricing pressure from Medicare Part D redesign, and macroeconomic softness in aesthetics. Pipeline execution risk remains high, as late-stage failures or delays could undermine the 2025+ growth narrative. Regulatory and policy uncertainty, especially around U.S. drug pricing legislation, could further challenge margins and innovation investment.
Forward Outlook
For Q3 2024, AbbVie guided to:
- Net revenues of approximately $14.2 billion (1.3% FX headwind expected)
- Adjusted EPS between $2.92 and $2.96 (excluding further IPR&D expense)
For full-year 2024, management raised guidance to:
- Total net revenues of approximately $55.5 billion (up $500 million)
- Adjusted EPS between $10.71 and $10.91
Management highlighted that all incremental sales growth comes from the ex-Humira platform, with Skyrizi, Rinvoq, and neuroscience expected to drive further gains. Aesthetics guidance was moderated for the year, but long-term targets remain unchanged.
- Medicare Part D redesign expected to create a ~3% growth headwind in 2025
- Humira erosion to slow in 2025, reducing drag on overall growth
Takeaways
AbbVie’s Q2 results reinforce the company’s strategic pivot to a diversified, innovation-led growth platform, with immunology and neuroscience outperformance offsetting legacy drug erosion and macro headwinds.
- Growth Platform Delivers: Robust execution in immunology and neuroscience is driving above-industry growth, validating AbbVie’s post-Humira strategy and supporting repeated guidance raises.
- Pipeline and BD Must Deliver: Sustained high-single-digit growth depends on successful late-stage readouts, regulatory wins, and continued business development, particularly as legacy headwinds persist.
- Watch for Margin and Policy Pressures: Investors should monitor Medicare, pricing, and macroeconomic risks, as well as the pace of aesthetics recovery and pipeline milestones, to assess the durability of AbbVie’s growth trajectory.
Conclusion
AbbVie’s Q2 performance demonstrates a broad-based return to growth, led by immunology and neuroscience, with the ex-Humira platform now the central earnings driver. The company’s ability to execute on pipeline launches and business development will be critical to sustaining its high-growth profile into the next decade.
Industry Read-Through
AbbVie’s results highlight the sector-wide imperative to diversify beyond legacy blockbusters, as biosimilar competition and pricing pressures intensify. The robust share gains for new mechanisms in immunology suggest that clinical differentiation and commercial agility can offset generic erosion, a lesson for peers facing similar patent cliffs. Aesthetics’ macro sensitivity and the muted recovery in China and the U.S. are cautionary signals for all consumer-discretionary healthcare segments. Finally, the volume of early-stage deals and pipeline focus on multispecifics and combination therapies signals an industry pivot toward next-generation innovation as the next growth engine.